Julie Andrews
Known title: DirectorCIK: 0001550508
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Transaction History
| RXST | ▲ Buy | Grant | 37,037 | — | 6/17/2026 | View on chart |
| OFIX | ▼ Sell | Open Market | 2,363 | $30K | 3/5/2026 | View on chart |
| OFIX | ▼ Sell | Open Market | 2,425 | $31K | 3/4/2026 | View on chart |
| OFIX | ▲ Buy | Grant | 35,495 | $0 | 3/3/2026 | View on chart |
| OFIX | ▼ Sell | Open Market | 4,873 | $70K | 1/16/2026 | View on chart |
| RXST | ▲ Buy | Grant | 10,752 | — | 6/3/2025 | View on chart |
| OFIX | ▲ Buy | Grant | 34,600 | $0 | 3/3/2025 | View on chart |
| OFIX | ▼ Sell | Open Market | 4,655 | $83K | 1/16/2025 | View on chart |
| RXST | ▼ Sell | Open Market | 11,940 | $691K | 6/14/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 3,685 | $216K | 6/14/2024 | View on chart |
| RXST | ▲ Buy | Grant | 2,554 | — | 6/6/2024 | View on chart |
| OFIX | ▲ Buy | Grant | 32,967 | $450K | 1/15/2024 | View on chart |
| RXST | ▲ Buy | Grant | 5,731 | $0 | 6/1/2023 | View on chart |
| RXST | ▲ Buy | Grant | 8,624 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.